Day One Biopharmaceuticals
Latest round
- Series B
Last raised
- Feb 2021
Total raised
- $190M
Investors
- 11
About Day One Biopharmaceuticals
Based in California, US, and founded in 2018, Day One Biopharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company that develops and commercializes targeted therapies for patients of all ages with genomically defined cancers. In March 2026, Servier agreed to fully acquire Day One Biopharmaceuticals, Inc.5 billion in equity value. The company trades in the NASDAQ-GS stock exchange under the ticker symbol DAWN. In addition, Day One Biopharmaceuticals employs 29 full-time employees. Day One Biopharmaceuticals offers accelerating medicines, DAY101, and Pimasertib to the patients. DAY101 is an oral and highly selective investigational pan-RAF inhibitor, which is under clinical development for the treatment of patients with relapsed or progressive low-grade glioma, or pLGG. Pimasertib is an oral, small-molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2 (MEK), of the MAPK signaling pathway. In addition, the company develops new insights from the biology of pediatric cancer and new therapies that meet the critical needs of people of all ages living with cancer, starting from the biology of childhood cancer, helping patients and doctors deal with cancer. Day One Biopharmaceuticals, Inc.
Who invested in Day One Biopharmaceuticals
11 investors across 2 rounds
See all investors in Day One Biopharmaceuticals
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Day One Biopharmaceuticals
Who invested in Day One Biopharmaceuticals?
Day One Biopharmaceuticals has 11 investors on record across 2 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Day One Biopharmaceuticals raised?
Day One Biopharmaceuticals has raised 2 venture rounds. Sign up free to see how much each round raised and the total.
When did Day One Biopharmaceuticals last raise money?
Day One Biopharmaceuticals's most recent round on record is a Series B, in Feb 2021.
What does Day One Biopharmaceuticals do?
Based in California, US, and founded in 2018, Day One Biopharmaceuticals, Inc.
Where is Day One Biopharmaceuticals headquartered?
Day One Biopharmaceuticals is headquartered in Brisbane, US.
Which VCs invest in companies like Day One Biopharmaceuticals?
Among active investors with capital left to deploy, Andreessen Horowitz, Founders Fund, Accel and Thrive Capital back biotechnology companies at Day One Biopharmaceuticals's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Day One Biopharmaceuticals? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.